Abstract
KN024 showed pembrolizumab improved survival compared to platinum doublet chemotherapy (PDC) in 1st-line setting for advanced NSCLC with PDL1≥50%. KN189/KN407 demonstrated pembrolizumab/PDC in advanced NSCLC achieved superior 12-month survival compared with PDC. In patients with PDL1≥50% cross 3 trials, objective response rate with pembrolizumab in KN024 was 45% compared to 60% with pembrolizumab/PDP in KN189/407. The clinical question is: can we distinguish this 45% of patients who are best treated with pembrolizumab alone, and who need additional PDC? Currently, there are no biomarkers or clinicopathological features to distinguish this population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
